Clinical Trials Logo

Renal Cell Carcinoma Recurrent clinical trials

View clinical trials related to Renal Cell Carcinoma Recurrent.

Filter by:
  • None
  • Page 1

NCT ID: NCT03634540 Active, not recruiting - Clinical trials for Renal Cell Carcinoma

A Trial of Belzutifan (PT2977, MK-6482) in Combination With Cabozantinib in Patients With Clear Cell Renal Cell Carcinoma (ccRCC) (MK-6482-003)

Start date: September 27, 2018
Phase: Phase 2
Study type: Interventional

This is an open-label Phase 2 study which will evaluate the efficacy and safety of belzutifan in combination with cabozantinib in participants with advanced ccRCC. Belzutifan and cabozantinib will be administered orally once daily.

NCT ID: NCT02974738 Active, not recruiting - Solid Tumor Clinical Trials

A Trial of Belzutifan (PT2977, MK-6482) Tablets In Patients With Advanced Solid Tumors (MK-6482-001)

Start date: December 7, 2016
Phase: Phase 1
Study type: Interventional

The primary objective of this study is to identify the maximum tolerated dose (MTD) of belzutifan Tablets and/or the recommended Phase 2 dose (RP2D) of belzutifan Tablets in patients with advanced solid tumors

NCT ID: NCT02577458 Recruiting - Clinical trials for Renal Cell Carcinoma Recurrent

Study of the Combination of CM082 With Everolimus in Patients With mRCC

Start date: September 2015
Phase: Phase 1
Study type: Interventional

This is a Phase I Dose-Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of CM082 in Combination with Everolimus in Chinese Patients With Advanced Renal Cell Carcinoma.